Angela Hurst
Women's Health · Moultrie, GANPI 1588328199
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,999 of the $5,265 with a category attached, or 75.9%. 26 manufacturers reported payments, led by Axonics, Inc. at 48.5% of the total. Reporting peaked in 2022 at $2,667 and has fallen 71.2% since, to $769 in 2025. Among women's health clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 172 payments — averaging $30.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$3K
- Sumitomo Pharma America, Inc.$449
- Astellas Pharma US Inc$433
- Urovant Sciences Inc$311
- GSK$186
- Myovant Sciences Inc.$163
- plus $1K from 20 others
What the payments were for
- Travel & lodging$1,06620%
- Food & beverage$3,99976%
- Education$2004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 62 | $2,555 |
| Sumitomo Pharma America, Inc. | 32 | $449 |
| Astellas Pharma US Inc | 11 | $433 |
| Urovant Sciences Inc | 26 | $311 |
| GSK | 3 | $186 |
| Myovant Sciences Inc. | 4 | $163 |
| AbbVie | 3 | $157 |
| Medtronic | 2 | $150 |
| Boston Scientific | 4 | $128 |
| Caris MPI, Inc. | 2 | $128 |
| Pfizer | 1 | $118 |
| Coloplast | 1 | $60 |
| Novartis | 3 | $52 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Lilly USA, LLC | 2 | $48 |
| Vertex | 2 | $43 |
| Merck | 2 | $37 |
| Eisai Inc. | 2 | $31 |
| UCB, Inc. | 1 | $25 |
| Endo Pharmaceuticals Inc. | 1 | $24 |
| Baxter Healthcare | 1 | $22 |
| Myriad Genetic Laboratories, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| Teleflex LLC | 1 | $20 |
| Bayer | 1 | $19 |
| Fennec Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics$1,291
- MYFEMBREE$121
- Veozah$117
- Elahere$117
- MI CANCER SEEK$109
How this compares
$5,265 in reported general payments places this provider in the 95th percentile of 247 women's health providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 290 | $225,028 |
| GemtesaVibegron | 251 | $182,544 |
| Estradiol | 178 | $11,838 |
| Trimethoprim | 125 | $8,432 |
| Solifenacin Succinate | 206 | $5,179 |
| NitrofurantoinNitrofurantoin Macrocrystal | 132 | $4,303 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 22 | $4,062 |
| Oxybutynin Chloride ErOxybutynin Chloride | 212 | $3,397 |
| Tolterodine Tartrate ErTolterodine Tartrate | 42 | $2,625 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 106 | $1,183 |
| Ciprofloxacin Hcl | 101 | $1,095 |
| Cephalexin | 95 | $1,021 |
| Fosfomycin Tromethamine | 15 | $999 |
| Nystatin | 89 | $824 |
| Gabapentin | 46 | $666 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $433 | $225,028290 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $449 | $182,544251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 247 women's health providers in Georgia.
Other women's health in Moultrie
- Sherri SellersSavannah$94K
- Jaclyn PiastaMarietta$8K
- Laurie RayAtlanta$5K
- Heather Thomas-OsuntokunAtlanta$3K
- Ania KirollosChamblee$3K
- Geneva RecordRinggold$3K
- Katie SellsSnellville$3K
- Susan AbbottAtlanta$3K
- Labrittany DavisAtlanta$3K
- Gretchen EichenlaubSavannah$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.